Mayo Biopsy Marker

Overview

About this study

This is a Phase 0 clinical trial to evaluate a twinkling biopsy marker (Patent Application Title: Non-Metallic Ultrasound-Detectable Markers Patent Application No.: 62/903,078, Application Type: Provisional) for ultrasound conspicuity in patients with breast cancer and locally advanced disease involving the axillary lymph nodes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node
Patient is not pregnant.
Surgical management involves preoperative radioactive seed localization of a previously identified positive axillary lymph node
Surgery will be performed by Dr. James Jakub.
Radioactive seed localization is scheduled at least one day prior to surgery.
No contraception is necessary or required.
English speaking

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Christine Lee, M.D., Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Christine Lee, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials